Date | Compound | Laboratory | Indication | Type of Information |
---|---|---|---|---|
2012-12-17 | vincristine sulfate liposome injection | Talon Therapeutics (USA) | Philadelphia chromosome negative (Ph-) acute lymphoblastic leukemia (ALL) | |
2014-10-15 | raxibacumab | GSK (UK) | inhalational anthrax | Granting of the orphan status in the EU |
2012-12-18 | influenza virus vaccine | GSK (UK) | active immunization of adults and children from 3 years of age for the prevention of influenza disease caused by the two influenza A virus subtypes and the two influenza B virus types contained in the vaccine |
Granting of a Market Authorisation in the EU |
2012-12-19 | combination LAMA/LABA (GSK573719 or umeclidinium bromide (UMEC) and vilanterol) | GSK (UK) Theravance (USA) | chronic obstructive pulmonary disease (COPD) |
Granting of a Market Authorisation in the EU |
2012-12-19 | botulinum toxin type A - onabotulinumtoxinA | Allergan (USA) | treatment of idiopathic overactive bladder (OAB) with symptoms of urinary incontinence, urgency and frequency in adult patients who have an inadequate response to, or are intolerant of, anticholinergic medications |
Granting of a Market Authorisation in the EU |
2013-02-12 | Japanese Encephalitis vaccine | Intercell (Austria) now Valneva | Japanese encephalitis |
Granting of a Market Authorisation in the EU |
2015-02-24 | deferasirox | Novartis (Switzerland) | treatment of chronic iron overload requiring chelation therapy when deferoxamine therapy is contraindicated or inadequate in patients aged 10 years and older with non-transfusion-dependent thalassemia (NTDT) syndromes |
Granting of the orphan status in the US |
2012-12-22 | eflornithine in combination with sulindac | Cancer Prevention Pharma (UK) | familial adenomatous polyposis | |
2012-12-22 | recombinant modified human growth hormone | Richardson Associates Regulatory Affairs Ltd (UK) | growth hormone deficiency |
Granting of the orphan status in the EU |
2013-01-24 | 1,2:5,6-dianhydrogalactitol | IDIS Ltd (UK) | glioma |
Granting of the orphan status in the EU |
2013-01-24 | adeno-associated viral vector serotype 9 containing the human N-acetylglucosaminidase alpha gene | Laboratorios del Dr. Esteve (Spain) | mucopolysaccharidosis type IIIB (Sanfilippo B syndrome) |
Granting of the orphan status in the EU |
2012-12-22 | allogeneic motor neuron progenitor cells derived from human embryonic stem cells | California Stem Cell (UK) Ltd | 5q spinal muscular atrophy |
Granting of a patent |
2012-12-22 | autologous CD34+ haematopoietic stem cells transduced with lentiviral vector encoding the human betaA-T87Q-globin gene | bluebird bio France (France) | beta-thalassemia intermedia and major |
Granting of a patent |
2012-12-22 | chimeric monoclonal antibody against claudin 6 | GANYMED Pharmaceuticals (Germany) | ovarian cancer | |
2012-12-22 | choline tetrathiomolybdate | Medical Need Europe AB (Sweden) | Wilson disease | Granting of the orphan status in the EU |
2013-01-24 | encapsulated human retinal pigment epithelial cell line transfected with plasmid vector expressing human ciliary neurotrophic factor | Enpharma Ltd (UK) | retinitis pigmentosa |
Granting of the orphan status in the EU |
2013-09-13 | lenalidomide | Celgene Europe (UK) | follicular lymphoma |
Granting of the orphan status in the US |
2012-12-22 | modified recombinant human C-type natriuretic peptide | BioMarin Europe (UK) | achondroplasia |
Granting of the orphan status in the EU |
2012-12-22 | recombinant human monoclonal antibody of the IgG1 kappa class against prostate stem cell antigen | Astellas Pharma Europe B.V | pancreatic cancer | |
2012-12-22 | terguride | Serodapharm (Germany) | systemic sclerosis |
© 2024 Biopharmanalyses - Powered by Samacom+